| Q28295583 | Cardiac Myosin Light Chain Kinase Is Necessary for Myosin Regulatory Light Chain Phosphorylation and Cardiac Performance in Vivo |
| Q47898693 | Cardiac contractility, motor function, and cross-bridge kinetics in N47K-RLC mutant mice. |
| Q34388932 | Cardiac-specific over-expression of epidermal growth factor receptor 2 (ErbB2) induces pro-survival pathways and hypertrophic cardiomyopathy in mice |
| Q34182820 | Cardiomyopathy-linked myosin regulatory light chain mutations disrupt myosin strain-dependent biochemistry |
| Q35910163 | Constitutive phosphorylation of cardiac myosin regulatory light chain prevents development of hypertrophic cardiomyopathy in mice |
| Q33949012 | Cross-bridge kinetics in myofibrils containing familial hypertrophic cardiomyopathy R58Q mutation in the regulatory light chain of myosin |
| Q34450885 | DCM-related tropomyosin mutants E40K/E54K over-inhibit the actomyosin interaction and lead to a decrease in the number of cycling cross-bridges. |
| Q37476496 | Discrete effects of A57G-myosin essential light chain mutation associated with familial hypertrophic cardiomyopathy |
| Q37257335 | Diversity and similarity of motor function and cross-bridge kinetics in papillary muscles of transgenic mice carrying myosin regulatory light chain mutations D166V and R58Q |
| Q37171740 | Echocardiographic Characterization of a Murine Model of Hypertrophic Obstructive Cardiomyopathy Induced by Cardiac-specific Overexpression of Epidermal Growth Factor Receptor 2. |
| Q33807092 | Effects of mild hypothermia on hemodynamics in cardiac arrest survivors and isolated failing human myocardium |
| Q35996464 | Electrocardiographic Characterization of Cardiac Hypertrophy in Mice that Overexpress the ErbB2 Receptor Tyrosine Kinase |
| Q44033619 | Evaluation of left ventricular diastolic function by global strain rate imaging in patients with obstructive hypertrophic cardiomyopathy: a simultaneous speckle tracking echocardiography and cardiac catheterization study |
| Q33942133 | Familial hypertrophic cardiomyopathy can be characterized by a specific pattern of orientation fluctuations of actin molecules . |
| Q35832615 | Functions of myosin light chain-2 (MYL2) in cardiac muscle and disease. |
| Q37726526 | Gene expression patterns in transgenic mouse models of hypertrophic cardiomyopathy caused by mutations in myosin regulatory light chain |
| Q26823478 | Getting the skinny on thick filament regulation in cardiac muscle biology and disease |
| Q90194760 | Global diastolic strain rate for the assessment of left ventricular diastolic dysfunction in young peritoneal dialysis patients: a case control study |
| Q33969167 | Hypertrophic cardiomyopathy associated Lys104Glu mutation in the myosin regulatory light chain causes diastolic disturbance in mice |
| Q49923294 | Hypertrophic cardiomyopathy mutation R58Q in the myosin regulatory light chain perturbs thick filament-based regulation in cardiac muscle |
| Q34726797 | Impact of familial hypertrophic cardiomyopathy-linked mutations in the NH2 terminus of the RLC on β-myosin cross-bridge mechanics |
| Q42270215 | Molecular and Functional Effects of a Splice Site Mutation in the MYL2 Gene Associated with Cardioskeletal Myopathy and Early Cardiac Death in Infants |
| Q28088824 | Molecular mechanisms of cardiomyopathy phenotypes associated with myosin light chain mutations |
| Q37021389 | Myosin light chains: Teaching old dogs new tricks |
| Q36832618 | Myosin regulatory light chain (RLC) phosphorylation change as a modulator of cardiac muscle contraction in disease |
| Q64915796 | Myosin regulatory light chain mutation found in hypertrophic cardiomyopathy patients increases isometric force production in transgenic mice. |
| Q36683854 | Myosin regulatory light chain phosphorylation enhances cardiac β-myosin in vitro motility under load |
| Q93087982 | Phosphomimetic-mediated in vitro rescue of hypertrophic cardiomyopathy linked to R58Q mutation in myosin regulatory light chain |
| Q39310427 | Pseudophosphorylation of cardiac myosin regulatory light chain: a promising new tool for treatment of cardiomyopathy. |
| Q90316748 | Regulatory light chain phosphorylation augments length-dependent contraction in PTU-treated rats |
| Q37256548 | Revisiting Frank-Starling: regulatory light chain phosphorylation alters the rate of force redevelopment (ktr ) in a length-dependent fashion |
| Q34696210 | Signaling to myosin regulatory light chain in sarcomeres |
| Q58542661 | Slow-twitch skeletal muscle defects accompany cardiac dysfunction in transgenic mice with a mutation in the myosin regulatory light chain |
| Q42850849 | Spontaneous Development of Left Ventricular Hypertrophy and Diastolic Dysfunction in Mice Lacking All Nitric Oxide Synthases |
| Q35556610 | The R21C Mutation in Cardiac Troponin I Imposes Differences in Contractile Force Generation between the Left and Right Ventricles of Knock-In Mice |
| Q28241457 | The effect of myosin RLC phosphorylation in normal and cardiomyopathic mouse hearts |
| Q43267509 | Type 1 diabetic cardiomyopathy in the Akita (Ins2WT/C96Y) mouse model is characterized by lipotoxicity and diastolic dysfunction with preserved systolic function |
| Q27025201 | Ultrasound biomicroscopy in small animal research: applications in molecular and preclinical imaging. |